PGHL · Health Care · 2026-08-21

Procter & Gamble Health Ltd

4.0WatchEven +1.2Stage 2 · wk 9In scan: Pullback Hunter · Prop Scan · Breakout WatchMARKET: BULL RISING · 2026-08-21
₹5,828.5
-0.07% today
₹9,675 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.

Visit company website →
P/E (TTM)
31.8
Forward 33.0
Earnings Growth (YoY)
-14.6%
Revenue +20.7%
Dividend Yield
3.84%
P/B 16.7
vs 52W High
-15.8%
₹4,778.6 lo₹6,918.5 hi
15.8% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 9
1w13w26w
Week 9 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
4.0%
200 DMA: ₹5,604.5 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.40x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -6.9% vs MA50 +2.3%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #68 of 84 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #48 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S2 14w
S2 20w
S2 33w
S2 23w
S4 18w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 14w → S3 11w → S2 20w → S3 3w → S4 8w → S1 2w → S2 33w → S3 13w → S2 23w → S3 9w → S4 18w → S1 5w → S2 9w current
Total tracked: 168 weeks across 13 stage runs.
1M
-13.1%
3M
+5.0%
6M
+15.3%
YTD
+6.4%
1Y
-4.6%
Scan Membership
Pullback Hunter
Latest: 2026-08-05
Prop Scan
Latest: 2026-08-05
Breakout Watch
Latest: 2026-06-22
46 appearances in last 60 days. First seen: 2024-07-10.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 9 · Vol —x
2026-08-20S2
Wk 9 · Vol —x
2026-08-19S2
Wk 9 · Vol —x
2026-08-18S2
Wk 9 · Vol —x
2026-08-17S2
Wk 8 · Vol —x
2026-08-14S2
Wk 8 · Vol —x
2026-08-13S2
Wk 8 · Vol —x
2026-08-12S2
Wk 8 · Vol —x
2026-08-11S2
Wk 8 · Vol —x
2026-08-10S2
Wk 7 · Vol —x
2026-08-07S2
Wk 7 · Vol —x
2026-08-06S2
Wk 7 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹6,368.2
200 DMA
₹5,604.5
52W High
₹6,918.5
52W Low
₹4,778.6
5D Low
₹5,781
Resistance levels (recent highs)
20d High
₹6,784
60d High
₹6,918.5
120d High
₹6,918.5
250d High
₹6,918.5
Next resistance
+16.4%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.